George Eric Davis - 02 Sep 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Reporting relationship: EVP, Chief Legal Officer
Issuer ticker: BMRN
Reported as of: 02 Sep 2026
Net transaction value: -$1,163,748
SEC form: 4
Accepted by SEC: 03 Sep 2026, 18:41:11 UTC
Prior SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Tae Sang Yoo, Attorney-in-Fact

Key filing fact

George Eric Davis filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 03 Sep 2026.

Key facts

This page summarizes George Eric Davis's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 18:41.

Change

Previous filing in this sequence was filed on 19 Mar 2026.
Current net transaction value: -$1,163,748.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001380710 Primary reporting owner

Davis George Eric

Relationship: EVP, Chief Legal Officer
Address: C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL
Signature: /s/ Tae Sang Yoo, Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BMRN transaction

Common Stock

Sale

Transaction value: $1,163,748
Shares: -17,557
Change %: -22%
Price: $66.28
Shares after: 61,003
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.